Posts Tagged ‘Rasilez’

December 20th, 2011

ALTITUDE Study of Aliskiren Terminated Early by Novartis

Novartis announced today the early termination of the ALTITUDE trial, which was testing the effect of the direct renin inhibitor aliskiren (Tekturna, Rasilez) in patients with type 2 diabetes and renal impairment at high risk for cardiovascular and renal events. The action was based on the recommendation of the independent Data Monitoring Committee, after it found […]